今年4月份，FDA派出两名官员检查了华海药业的成品药工厂。
In April, the FDA sent two officials to inspect Huahai's finished-dosage factory.
华海药业过去的业务重点是高血压药物，但现在已开始生产多种仿制药。
Huahai used to focus on hypertension drugs but now makes a stable of generic medicines.
华海药业有90%的收入来自于原料药，其产品出口到了30多个国家。
Huahai currently gets 90% of its revenue from APIs, most of which are exported to drug companies in more than 30 countries.
华海药业工作人员也表示，目前，已对出口的影响不大，很难预测未来。
Staff also said that at present, has little effect on exports is difficult to predict the future.
华海药业负责北美和日本市场销售的区域代表JessicaYu说，目前，我们认为还不具备从事专利药研究的能力或技术知识。
'Currently, we don't think we have that kind of capability or technical knowledge of doing a patent,' says Jessica Yu, Huahai's regional representative for North American and Japanese drug sales.
华海药业负责北美和日本市场销售的区域代表JessicaYu说，目前，我们认为还不具备从事专利药研究的能力或技术知识。
'Currently, we don't think we have that kind of capability or technical knowledge of doing a patent,' says Jessica Yu, Huahai's regional representative for North American and Japanese drug sales.
应用推荐